HTR2B

5-hydroxytryptamine receptor 2B · P41595 · HTR2B on Sugi Atlas →

558,740 patent compounds predicted against HTR2B, 358,930 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Amitriptyline (SCHEMBL7824)	1.00	8/20
SCHEMBL13777	0.57	6/20
SCHEMBL13778	0.57	6/20
Mianserin (SCHEMBL18020)	1.00	5/20
Prochlorperazine (SCHEMBL18429)	1.00	5/20
Ergotamine (SCHEMBL1483)	1.00	4/20
Cyproheptadine (SCHEMBL4021)	1.00	4/20
Fenfluramine (SCHEMBL16215)	1.00	4/20
Dexfenfluramine (SCHEMBL16706)	1.00	4/20
Ergotamine (SCHEMBL8045)	0.93	4/20
Ergotamine (SCHEMBL8046)	0.93	4/20
Oxprenolol (SCHEMBL16310)	0.72	4/20
Oxprenolol (SCHEMBL16311)	0.72	4/20
SCHEMBL1336	0.67	4/20
SCHEMBL979	0.63	4/20
SCHEMBL1484	0.62	4/20
SCHEMBL1101	0.60	4/20
SCHEMBL578	0.57	4/20
SCHEMBL952	0.55	4/20
Simvastatin (SCHEMBL2471)	1.00	3/20

Clinical trials — most relevant to HTR2B by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Relationship Among Changes in Brain Network Activation in Adult Outpatients With Major Depressive Disorder	PHASE4	COMPLETED
Monoamine Contributions to Neurocircuitry in Eating Disorders	PHASE4	COMPLETED
Study to Evaluate AD04 in Adults With Alcohol Use Disorder (AUD) and Selected Serotonin Transporter Polymorphisms	PHASE3	COMPLETED
Psilocybe Cubensis Mushrooms With or Without Fluoxetine for Refractory Depression	PHASE1/PHASE2	RECRUITING
Psilocybin With Pimavanserin Compared to Psilocybin Alone for the Treatment of Major Depressive Disorder	PHASE2	RECRUITING
Efficacy of Psilocybin and Trazodone Combination in Treatment-resistant Depression: a Randomized Controlled Proof-of-concept Study (PSILOTRAZ)	PHASE2	NOT_YET_RECRUITING
5HT2CR Balance in Brain Connectivity in Cocaine Dependence	PHASE1/PHASE2	COMPLETED
Clinical, Neurocognitive, and Emotional Effects of Psilocybin in Depressed Patients - Proof of Concept	PHASE2	COMPLETED
An Investigation of the Antidepressant Efficacy of the 5-HT2A Antagonist, M100907, in Combination With Citalopram in Treatment Resistant Depression	PHASE2	COMPLETED
The Effect of Ginger on the Incidence of Postoperative Nausea and Vomiting	PHASE2	COMPLETED
Effects of SERT Inhibition on the Subjective Response to Psilocybin in Healthy Subjects	PHASE1	COMPLETED
Psilocybin and Methylenedioxymethamphetamine (MDMA) for Post-traumatic Stress Disorder (PTSD)	PHASE1	RECRUITING
The Neurobiological Effect of 5-HT2AR Modulation	PHASE1	RECRUITING
Acute Effects of 2C-B Compared With MDMA and Psilocybin in Healthy Subjects	PHASE1	COMPLETED
SRC Inhibition as a Potential Target for Parkinson's Disease Psychosis	EARLY_PHASE1	UNKNOWN
Epigenetic and Neurochemical Correlates of Bipolar Disorder	nan	NOT_YET_RECRUITING
Correlation Between Peri-implantitis and Assumptions of Medications	nan	COMPLETED
The Role of 5-HT2A Receptor in the Perception of Self and Personal Meaning in Healthy Volunteers	nan	COMPLETED
Evaluation of [11C]Cimbi-36 as an Agonist PET Radioligand for Imaging of 5-HT2A Receptors	nan	COMPLETED
Investigating the Neuropsychological Effects of 5-HT2a Antagonism	nan	RECRUITING
Examination of Brain Serotonin Receptors in Patients With Mood Disorders	nan	COMPLETED
Microdosing LSD in Women With Premenstrual Disorders	nan	NOT_YET_RECRUITING
The Pill Project - Oral Contraceptive and Serotonergic Brain Signaling	nan	UNKNOWN
5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis	nan	COMPLETED
Genetic Variants Associated With Adolescent Suicide Attempts	nan	COMPLETED
PET Whole Body Distribution Studies Using [11C]CUMI	nan	COMPLETED
Using Fenfluramine to Test the Serotonin Deficiency Theory of Depression	nan	NOT_YET_RECRUITING
Effect of Psilocybin on the Positive Valence System in Treatment-resistant Depression	nan	COMPLETED
Trazodone and the Risk of Serious Adverse Events	nan	COMPLETED
TSK (Tryptophan - Serotonin - Kynurenine) Biomarkers Assessment in Stroke	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a HTR2B binder may also engage these)

Protein	Name	Similarity
Q02152	—	0.996	Q02152 →
Q8UUG8	—	0.992	Q8UUG8 →
P30994	—	0.992	P30994 →
Q5R4Q6	—	0.990	Q5R4Q6 →
P18901	—	0.989	P18901 →
Q9N2A4	—	0.988	Q9N2A4 →
DRD1	D(1A) dopamine receptor	0.987	landscape →
O46635	—	0.987	O46635 →
DRD2	D(2) dopamine receptor	0.987	landscape →
HTR2C	5-hydroxytryptamine receptor 2C	0.987	landscape →
P31390	—	0.986	P31390 →
P42288	—	0.986	P42288 →
Q95136	—	0.986	Q95136 →
Q6TLI9	—	0.986	Q6TLI9 →
Q75Z89	—	0.986	Q75Z89 →
P60026	—	0.986	P60026 →
P52702	—	0.986	P52702 →
Q19084	—	0.986	Q19084 →
Q16950	—	0.985	Q16950 →
P08909	—	0.985	P08909 →
P18599	—	0.985	P18599 →
P50130	—	0.985	P50130 →
P42289	—	0.985	P42289 →
P53452	—	0.985	P53452 →
P14842	—	0.985	P14842 →
P53453	—	0.985	P53453 →
O73810	—	0.985	O73810 →
P70174	—	0.984	P70174 →
P50129	—	0.984	P50129 →
HTR2A	5-hydroxytryptamine receptor 2A	0.984	landscape →